{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:11Z","timestamp":1790957951394,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115369"],"award-info":[{"award-number":["115369"]}]},{"name":"European Union\u2019s Seventh Framework Programme","award":["FP7\/2007-013"],"award-info":[{"award-number":["FP7\/2007-013"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejpb.2018.09.022","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T15:57:14Z","timestamp":1537891034000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer"],"prefix":"10.1016","volume":"132","author":[{"given":"C.","family":"Roos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejpb.2018.09.022_b0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrmicro3050","article-title":"The abundance and variety of carbohydrate-active enzymes in the human gut microbiota","volume":"11","author":"El Kaoutari","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"issue":"5883","key":"10.1016\/j.ejpb.2018.09.022_b0010","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1126\/science.1155725","article-title":"Evolution of mammals and their gut microbes","volume":"320","author":"Ley","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12182","article-title":"The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system","volume":"260","author":"Pelaseyed","year":"2014","journal-title":"Immunol. Rev."},{"issue":"2\u20133","key":"10.1016\/j.ejpb.2018.09.022_b0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cocis.2005.11.001","article-title":"Mucin structure, aggregation, physiological functions and biomedical applications","volume":"11","author":"Bansil","year":"2006","journal-title":"Curr. Opin. Colloid Interface Sci."},{"issue":"39","key":"10.1016\/j.ejpb.2018.09.022_b0025","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0803124105","article-title":"The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria","volume":"105","author":"Johansson","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2018.09.022_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041009","article-title":"Fast renewal of the distal colonic mucus layers by the surface goblet cells as measured by in vivo labeling of mucin glycoproteins","volume":"7","author":"Johansson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.09.022_b0035","article-title":"Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis","author":"Johansson","year":"2013","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ejpb.2018.09.022_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0966-842X(00)88906-4","article-title":"Bacterial translocation from the gastrointestinal tract","volume":"3","author":"Berg","year":"1995","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0045","first-page":"82","article-title":"Poor aqueous solubility\u2014an industry wide problem in drug discovery","volume":"5","author":"Lipinski","year":"2002","journal-title":"Am. Pharm. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.09.022_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1211\/0022357055263","article-title":"The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension","volume":"57","author":"Lennern\u00e4s","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0065","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2018.09.022_b0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11095-008-9750-9","article-title":"Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products","volume":"26","author":"Fatouros","year":"2009","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2018.09.022_b0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/acs.molpharmaceut.5b00774","article-title":"Gastrointestinal motility variation and implications for plasma level variation: oral drug products","volume":"13","author":"Talattof","year":"2016","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2018.09.022_b0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1018836727001","article-title":"The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities","volume":"16","author":"Kaus","year":"1999","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0085","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/ja02086a003","article-title":"The rate of solution of solid substances in their own solutions","volume":"19","author":"Noyes","year":"1897","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.ejpb.2018.09.022_b0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.addr.2007.05.003","article-title":"Nanosizing\u2014oral formulation development and biopharmaceutical evaluation","volume":"59","author":"Kesisoglou","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0095","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3109\/03639040903025855","article-title":"Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development","volume":"35","author":"Sigfridsson","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2018.09.022_b0100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1023\/A:1019829622088","article-title":"Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography\/mass spectrometry","volume":"19","author":"Jia","year":"2002","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2018.09.022_b0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","article-title":"Nanosizing: a formulation approach for poorly-water-soluble compounds","volume":"18","author":"Merisko-Liversidge","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2018.09.022_b0110","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019216","article-title":"Small but mighty: cell size and bacteria","volume":"7","author":"Levin","year":"2015","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"4","key":"10.1016\/j.ejpb.2018.09.022_b0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","article-title":"Biodegradable nanoparticles for drug delivery and targeting","volume":"6","author":"Hans","year":"2002","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0120","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jps.2600691204","article-title":"Analysis of models for determining intestinal wall permeabilities","volume":"69","author":"Amidon","year":"1980","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2018.09.022_b0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0928-0987(95)00027-B","article-title":"Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption","volume":"3","author":"Fagerholm","year":"1995","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0130","doi-asserted-by":"crossref","first-page":"G593","DOI":"10.1152\/ajpgi.1992.262.3.G593","article-title":"Human jejunal unstirred layer: evidence for extremely efficient luminal stirring","volume":"262","author":"Levitt","year":"1992","journal-title":"Am. J. Physiol.-Gastrointes. Liver Physiol."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0135","doi-asserted-by":"crossref","first-page":"G325","DOI":"10.1152\/ajpgi.1987.252.3.G325","article-title":"Quantitative assessment of luminal stirring in the perfused small intestine of the rat","volume":"252","author":"Levitt","year":"1987","journal-title":"Am. J. Physiol.-Gastrointes. Liver Physiol."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0140","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.molpharmaceut.7b00294","article-title":"In vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.09.022_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2009.12.014","article-title":"Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect","volume":"387","author":"Sugano","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-201x.1999.00510.x","article-title":"Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag","volume":"165","author":"Fagerholm","year":"1999","journal-title":"Acta Physiol. Scand."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0160","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1023\/A:1012144232666","article-title":"Rat jejunal permeability and metabolism of \u03bc-selective tetrapeptides in gastrointestinal fluids from humans and rats","volume":"14","author":"Krondahl","year":"1997","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0165","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional intestinal permeability in rats: a comparison of methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2018.09.022_b0170","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/mp500152y","article-title":"The low\/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol","volume":"11","author":"Zur","year":"2014","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2018.09.022_b0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00505943","article-title":"Rat jejunum perfused in situ: effect of perfusion rate and intraluminal radius on absorption rate and effective unstirred layer thickness","volume":"307","author":"Winne","year":"1979","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejpb.2018.09.022_b0180","doi-asserted-by":"crossref","first-page":"G1169","DOI":"10.1152\/ajpgi.2001.281.5.G1169","article-title":"inhibition excites enteric nerves that affect motility, alkaline secretion, and permeability in rat duodenum","volume":"281","author":"Nylander","year":"2001","journal-title":"Am. J. Physiol.-Gastrointes. Liver Physiol."},{"key":"10.1016\/j.ejpb.2018.09.022_b0185","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of five model compounds and the intestinal barrier marker 51Cr-EDTA","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.ejpb.2018.09.022_b0190","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/nmo.12410","article-title":"Quantifying the effects of inactin vs Isoflurane anesthesia on gastrointestinal motility in rats using dynamic magnetic resonance imaging and spatio-temporal maps","volume":"26","author":"Ailiani","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejpb.2018.09.022_b0195","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.7b00294","article-title":"In vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0200","doi-asserted-by":"crossref","first-page":"G95","DOI":"10.1152\/ajpgi.00074.2013","article-title":"Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo","volume":"305","author":"Sommansson","year":"2013","journal-title":"Am. J. Physiol.-Gastrointes. Liver Physiol."},{"issue":"4","key":"10.1016\/j.ejpb.2018.09.022_b0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1748-1716.2006.01649.x","article-title":"Modulation of mucosal permeability by vasoactive intestinal peptide or lidocaine affects the adjustment of luminal hypotonicity in rat duodenum","volume":"189","author":"Nylander","year":"2007","journal-title":"Acta Physiol."},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-5173(95)04204-0","article-title":"Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo","volume":"127","author":"Lennern\u00e4s","year":"1996","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2018.09.022_b0215","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejps.2013.05.019","article-title":"In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim","volume":"49","author":"Sj\u00f6gren","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2018.09.022_b0220","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of model compounds and the mucosal barrier marker 51Cr-EDTA","volume":"14","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jps.2600710120","article-title":"Theoretical and experimental studies of transport of micelle-solubilized solutes","volume":"71","author":"Amidon","year":"1982","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.09.022_b0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijpharm.2004.08.001","article-title":"The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human","volume":"285","author":"Wu","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.09.022_b0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano-and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2018.09.022_b0240","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2018.09.022_b0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2010.05.009","article-title":"Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans","volume":"76","author":"Shono","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.09.022_b9000","unstructured":"National Center for Biotechnology Information. PubChem Compound Database; CID = 6918365. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6918365 (13 March)."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118307604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118307604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:31:39Z","timestamp":1760545899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118307604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":50,"alternative-id":["S0939641118307604"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.09.022","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}